"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study"

Figures

• 

  Fig. 1. This chart displays the same outcomes as the 5-year chart but over a 1-year period.The outcomes for Warfarin are slightly higher for All-Cause Mortality and Major GI Bleeding compared to DOACs, but the percentages are generally closer between the two groups compared to the 5-year data.The p-values, ranging from 0.108 to 1.000, also indicate no statistically significant differences, suggesting that both treatments have comparable safety profiles for these outcomes within one year.

• 

  Fig. 2. This chart compares the percentage of adverse outcomes CVAs, All-Cause Mortality, Major GI Bleeding, and CNS Bleeding between patients on Warfarin and those on DOACs over a 5-year period. Warfarin shows slightly higher percentages across most outcomes, particularly in All-Cause Mortality and Major GI Bleeding, however didn't reach statistically significant difference.

• 

  Fig. 3. 1-year Kaplan-Meier curve showed slightly higher survival for the DOAC group (90.3 %) compared to warfarin (86.5 %) in patients with a BMI ≥50 kg/m2, suggesting a potential short-term survival benefit with DOACs, though not statistically significant.

• 

  Fig. 4. 5-year Kaplan-Meier Survival Curve showed that DOAC group again demonstrated better survival (83.6 % vs. 81.1 % for warfarin), with a consistent trend favoring DOACs in long-term outcomes for these patients, though statistical significance was not reached.